Christopher Fried

Christopher Fried has worked in a variety of roles in the scientific field since 2003. In 2003, they began as an Undergraduate Research Assistant at the Mount Desert Island Biological Lab. In 2004, they worked as an Undergraduate Research Assistant at the Marine Biological Lab, where they performed cell biological and live-imaging microscopy experiments, attended lectures for the graduate level summer course in Physiology, and presented research results at a symposium. In 2005, they worked as a Graduate Student at Carnegie Mellon University, where they designed and successfully completed Doctoral-level experiments to elucidate the molecular mechanisms of colon cancer formation. From 2008 to 2009, they worked as a Laboratory Assistant at H.J. Heinz Co and then as a Clinical Laboratory Technician II at Precision Therapeutics, where they prepared human malignant epithelial cell cultures for robotic plating procedures and initiated, monitored, and maintained human primary tissue cultures. In 2010, they worked as a Research Assistant at the Magee-Womens Research Institute, where they established and maintained cell cultures and performed flow cytometric analyses on human whole blood samples and dissected and cultured human placental tissue. From 2011 to 2021, they worked as an Associate Scientist and Research Associate at Noveome Biotherapeutics, Inc. In 2021, they began as a Research Associate at BlueSphere Bio, and in 2022, they began as a Bioassay Scientist at Carmell Therapeutics.

Christopher Fried attended Dickinson College from 2001 to 2005, where they earned a Bachelor of Science in Biochemistry & Molecular Biology and Biology. Christopher then went on to Carnegie Mellon University from 2005 to 2007, where they earned a Master of Science in Biological Sciences.